Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 3Other hematologic neoplasm 2Gynecologic 2Genitourinary 2Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Stomach Neoplasms 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

Specimen Handling 36Magnetic Resonance Spectroscopy 31Cyclophosphamide 26Doxorubicin 23Biopsy 22pembrolizumab 21Temozolomide 21X-Rays 17Radiotherapy 17Radiation 16Nivolumab 13atezolizumab 12Vincristine 12Phantoms, Imaging 12Irinotecan 12Ifosfamide 12Gemcitabine 12fludarabine 11cabozantinib 10liposomal doxorubicin 8Surgical Procedures, Operative 8Ipilimumab 8Etoposide 8Bevacizumab 8Paclitaxel 7Immunoglobulin G 7Carboplatin 7palbociclib 6olaparib 6fludarabine phosphate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ceralasertib × Sarcoma × 90 days × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡